A paper by Campbell et al. (2024) provides some guidance. The authors developed a series of recommendations based on literature review, expert interviews and an expert workshop in order to support consistent and transparent evaluation and use of validated family spillover effects in health technology assessments (HTA) and cost-effectiveness analyses (CEA). The expert panel consisted of 2 patient advocates, 2 health economists, 2 outcomes researchers, 1 health policy expert, and 1 payer.
Based on this approach, the experts settled on 15 recommendations with medium to high consensus. The recommendations were made for 3 different stakeholder groups: (i) HTA agencies, (ii) researchers who develop models, and (iii) researchers who collect and analyze data on family spillovers. These recommendations are listed in the table below.
For more context on these recommendations, do read the full article here.
Disclaimer :
This article is solely for informational purposes, any medical information contained is not a substitute for professional medical advice and readers should not rely on it as such.
If you believe there may be errors or misinformation in this article, we encourage you to contact the webmasters by messaging the provided contact information.
Your feedback is valuable, and we are committed to rectifying any inaccuracies. Please note that the content will be re-evaluated, and corrections will be made as necessary following your submission.